Engchem Life Sciences to Participate in JP Morgan Healthcare Conference... "Discussions on Technology Licensing and More"

Countries around the world are competing to develop vaccines and treatments to overcome COVID-19. The domestic bio venture company Engicam Life Sciences is conducting Phase 2 clinical trials after receiving approval for a new drug substance from the U.S. Food and Drug Administration (FDA). Ahead of the New Year 2021, a researcher is studying the COVID-19 treatment EC-18 at Engicam Life Sciences Central Research Institute in Jecheon, Chungbuk. Photo by Jinhyung Kang aymsdream@

[Asia Economy Reporter Kim Daehyun] Engchem Life Sciences announced on the 4th that it has been officially invited to participate in the 40th 'JP Morgan Healthcare Conference' held from the 10th to the 13th.

At this conference, Engchem Life Sciences plans to hold about 30 meetings with global pharmaceutical companies regarding its anticancer combination therapy (CRIOM, a treatment for chemotherapy and radiotherapy-induced oral mucositis).

The JP Morgan Healthcare Conference is the world's largest pharmaceutical and biotech event, with about 1,500 companies from over 40 countries participating. Engchem Life Sciences, participating for the fourth consecutive year, has completed a pre-interview with the US investment media 'DataSite' and will announce the results of the US Phase 2 clinical trial of the CRIOM treatment on the 13th through the 'Biotech Showcase 2021'.

Engchem Life Sciences has completed the US Phase 2 clinical trial of the CRIOM treatment and secured the best results among clinical trials conducted for this indication. Based on the trial results, it completed the application for 'Breakthrough Therapy Designation (BTD)' with the US Food and Drug Administration (FDA) in November last year and is actively pursuing large-scale technology exports with global pharmaceutical companies.

Engchem Life Sciences plans to complete the protocol design necessary for Phase 3 clinical trials in consultation with the FDA in the first half of this year and submit an IND (Investigational New Drug) application. In the future, to increase the clinical success rate of the CRIOM treatment, joint clinical trials with global pharmaceutical companies will also be conducted.

An Engchem Life Sciences official said, "If designated as BTD by the FDA, 'EC-18' from Engchem Life Sciences will be the only treatment option for CRIOM patients who have had no treatment options until now," adding, "At this conference, meetings are scheduled with 30 global pharmaceutical companies and top-tier investors to discuss technology exports as well as to establish strategic investment partnerships."

This content was produced with the assistance of AI translation services.